Welcome to health book

Day of S ＊ Bio11 announces, develop a kind of code name successfully already to be the medicaments of patent profess to convinced of SB1518, will use at treating the hematic cancer of disease of medullary and proliferous sex and certain type.

Disease of medullary and proliferous sex is a kind of rare blood cancer, medullary cell organizes unusual hyperplasia, cause erythrocyte and plaque overmuch, and the issue that medullary fiber turns. New pharmaceuticals brings about the signal with medullary unusually progenitive cell through interference, will suspend the multiply with factitious cell and disrupt action.

Abecedarian experiment shows, new pharmaceuticals is mixed inside test tube inside live body, can obtain the result that restrains medullary cell hyperplasia and antagonism tumour.

President of company of S ＊ Bio Dr. Kaersen points out, patient of disease of medullary and proliferous sex lacks specific aim and long-term remedial method, once new pharmaceuticals develops a success, aux will be able to offers a gleam of hope for these patients.

This is S ＊ Bio in the past inside 12 months, in the 2nd when the respect of research and development of anticarcinogen content obtains major breakthrough. The first by the anticarcinogen content of Singapore laboratory research and development also be by research and development of company of S ＊ Bio, just developed the clinical trial of the first phase in June this year.

Content predicts the new anticarcinogen of SB1518 to begin the clinical test of the first phase first half of the year next year. If the test is successful, medicaments will roll out the market after 5 years.

S ＊ Bio is Singapore Economic Development Board in 2 OOO year as joint-stock as ChironCorporation of company of science and technology of American California biology those who open. Chiron was made by Switzerland last year company of medical Shang Nuohua (Novartis) is bought.